CompanyDNTHNasdaqNew York, NY

Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics develops therapies for severe autoimmune diseases.

SEC EDGAR ClinicalTrials.gov dianthustx.com

8-KSep 11Latest SEC filing, period to Sep 8

Aug 10Latest story

August 2026

Dianthus reports Phase 3 CIDP interim data and gMG trial start, $1.2 billion cash

Aug 4Quarterly updateDianthus Therapeutics, Inc. /DE/